the Paradise Ultrasound Renal Denervation system offers a much-needed advancement in our currently available options to control hypertension," site principal investigator Naomi Fisher, MD, associate professor of medicine, Harvard Medical School, and director of hypertension service and hypertension ...
November 7, 2023—Recor Medical announced it has received United States FDA approval for its Paradise ultrasound renal denervation (RDN) system for the treatment of hypertension. A subsidiary of Otsuka Medical Devices Co. Ltd., Recor notes that the Paradise system is intended as an...
Renal denervationResistant hypertensionThe ReCor Medical Paradise庐 Renal Denervation System delivers ultrasound energy to perform targeted circumferential denervation to the renal afferent and efferent sympathetic nerves with the goal of achieving a reduction in systemic arterial blood pressure, and mitigating ...
The results come from an analysis of the pooled data from ReCor’s RADIANCE global clinical trial program, which includes three prospectively powered, randomized, and sham-controlled clinical trials evaluating the endovascular Paradise ultrasound renal denervation (uRDN) system i...
The article reports on the CE mark attained by ReCor Medical's Percutaneous Renal Denervation system (PARADISE) ultrasound platform. The platform is used to treat patients with resistant hypertension...
The article reports on the CE mark attained by ReCor Medical's Percutaneous Renal Denervation system (PARADISE) ultrasound platform. The platform is used to treat patients with resistant hypertension (HTN). It includes a 5 French-compatible catheter with a cylindrical transducer which emits ultrasound...
TCT-497 Arterial Media Preservation Associated with The Paradise Ultrasound Renal Denervation System: A Next generation Approach for Treating Resistant Hypertensiondeforestationforestsland uselandsatmathematical modelsremote sensingsatellite imagerysecondary forests...
FDA OKs Paradise Renal Denervation system for hypertensionJeffrey, SusanCardiology News
Overview of the 2023 FDA Circulatory System Devices Advisory Panel meeting on the Recor Paradise Ultrasound‐Based Renal Denervation Systemdoi:10.1002/ccd.31065Haberman, DanChitturi, Kalyan R.Lupu, LiorWermers, Jason P.Waksman, RonCatheterization & Cardiovascular Interventions...
ReCor claims that Paradise is the only system for renal denervation based on ultrasound energy. Chief executive officer (CEO) Mano Iyer claims that the clinical results provide ReCor with competitive advantage over makers of radiofrequency-based systems for hypertension....